There are currently no items available.

Corporate Profile

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine. Patients have been and continue to be at the center of our 17-year corporate history.

Keryx established its corporate headquarters in Boston to support the U.S. launch of its first medicine. Joining Boston’s pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 185 full-time employees across Boston, New York, and our field team.

Stock Quote

KERX (Common)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.11 (2.31%)
Data as of 02/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Report

View the 2015 Annual Report on Form 10K  - PDF View the 2015 Annual Report on Form 10K

Recent News

02/23/17Keryx Biopharmaceuticals to Webcast its Presentations at Two Investor Conferences in March 2017Printer Friendly Version
02/16/17Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017Printer Friendly Version
02/08/17Keryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' 2017 Global Healthcare Conference on February 22, 2017Printer Friendly Version
01/12/17Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of NephrologyPrinter Friendly Version

Upcoming Events

8:00 a.m. ET
Q4 2016 Keryx Biopharmaceuticals, Inc. Earnings Conference Call
8:40 a.m. ET
Keryx Biopharmaceuticals, Inc. at Raymond James 38th Annual Institutional Investors Conference
10:00 a.m. ET
Keryx Biopharmaceuticals, Inc. at 37th Annual Cowen and Company Healthcare Conference

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.